VolitionRX Ltd (NYSEAMERICAN:VNRX) was the recipient of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 148,679 shares, a decline of 14.5% from the January 31st total of 173,884 shares. Based on an average daily trading volume, of 77,930 shares, the short-interest ratio is currently 1.9 days. Approximately 0.8% of the shares of the stock are short sold.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of VolitionRX in a research note on Monday, January 29th.
VolitionRX (NYSEAMERICAN:VNRX) opened at $3.06 on Thursday. VolitionRX has a 52 week low of $2.08 and a 52 week high of $4.71. The company has a market cap of $78.50, a PE ratio of -5.88 and a beta of -0.97.
TRADEMARK VIOLATION WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3229535/volitionrx-ltd-vnrx-short-interest-update.html.
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.